Call for funding - SFO Stem cells and Regenerative medicine 2021
The aim of the SFO Stem cells and Regenerative medicine is to support research and infrastructure within the field of stem cells and regenerative medicine. The SFO will support researchers, research programs and infrastructure at the Karolinska Institutet (KI) with or without collaboration with the health care system based on scope, quality, and the potential to strengthen and develop the field.
The SFO for Stem Cells and Regenerative Medicine has decided to allocate up to 24 million SEK for research grants according to the same strategy as for previous years. Grants will be allocated for 2021 but depending on governmental decisions successful applicants may be awarded grants for a second year (2022) without new application. Previous and currently supported infrastructures and researchers from SFO Stem Cells and Regenerative Medicine are presented at the website.
This years' call encompasses basic and clinical research grants. Due to regulations, the grants for this period will be distributed 2021, with a disposition time until 31 Dec 2022.
The SFO will during 2021 support up to 6 junior research grants and up to 5 senior research grants for projects within the field of stem cells and regenerative medicine. The senior grants are open to all candidates and the junior grants are open to candidates up to 12 years after obtaining their PhD. Applicants should be affiliated 100% at KI and/or the Stockholm County Council (SLL) at the time of starting the project. Applicants who received grants from this SFO with a disposition right including 2021 are not eligible to apply.
Eligible projects will be supported with a total of 2 MSEK/year. Grants can be used to cover salaries, running costs, equipment and administrative costs. Indirect costs for the research project specified in the application must not exceed the INDI level at the receiving department. A researcher is limited to submit only one application for a research grant or a clinical research grant.
Clinical research grants
The SFO will during 2021 support up to 4 clinical-translational research grants for projects within the area of stem cells, regenerative medicine and cellular therapies. The call is open to all candidates. These grants aim at supporting clinically active physicians, who have both an MD and a PhD degree and are affiliated 100% to SLL and KI at the time of starting the project. During the period of research support, the applicant should perform clinical work corresponding at least 20% of full time and be employed as “ST läkare” or specialist at a clinical department within SLL. Examples encompass, however are not restricted to, clinical trials, development of ATMP products or other essential steps for planned clinical trials, correlative biological studies for clinical trials and diagnostic and biomarker studies, all with relevance for the field.
Eligible projects will be supported with a total of 2 MSEK/year. Grants can be used to cover salaries, running costs, equipment and administrative costs. Indirect costs for the research project specified in the application must not exceed the INDI level at the receiving institution. A researcher is limited to submit only one application for a research grant or a clinical research grant.
Relevance for the field – who can apply?
Stem cells play an important role in the development, homeostasis and regeneration of tissues. Malfunctions in stem cells may lead to several types of disease. Stem cell research is rapidly expanding our understanding of these processes. Stem cell therapies are established in clinical medicine for malignant as well as for non-malignant conditions and novel therapies are continuously being developed, several of which had entered into preclinical and clinical trials. Applicants involved in research programs with relevance for the above-described fields are welcome to submit an application. PIs in the process of being recruited to KI or KS and who will be employed within 2021 are also eligible, but will require a detailed letter of support by the chair of the receiving department and / or clinical department.